While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

A factor that has changed over time is hospitalization due to severe COVID infections. On Aug. 1, the statewide seven-day ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.